CVE:MFSMedifocus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medifocus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.01 -0.01 (-33.33 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.01Now: C$0.01▼C$0.0250-Day RangeC$0.01MA: C$0.01▼C$0.0252-Week RangeC$0.01Now: C$0.01▼C$0.02Volume159,000 shsAverage Volume343,049 shsMarket CapitalizationC$1.85 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsEarningsHeadlinesSocial Media Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus Inc. has a patent license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases. The company is based in Columbia, Maryland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medifocus. Previous Next 2.5 Community Rank Outperform VotesMedifocus has received 54 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedifocus has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedifocus has received 50.91% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medifocus and other stocks. Vote “Outperform” if you believe MFS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MFS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedifocus does not currently pay a dividend.Dividend GrowthMedifocus does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifocus insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifocus is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifocus is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:MFS Previous Symbol CUSIPN/A CIKN/A Webwww.medifocusinc.com Phone+1-905-3197070Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$2.23 million Price / Sales0.83 Cash FlowC$0.00 per share Price / Cash Flow10.00 Book ValueC($0.07) per share Price / Book-0.15Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees7 Outstanding Shares184,984,000Market CapC$1.85 million Next Earnings Date9/3/2020 (Estimated) OptionableNot Optionable C$0.01 -0.01 (-33.33 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MFS News and Ratings via Email Sign-up to receive the latest news and ratings for MFS and its competitors with MarketBeat's FREE daily newsletter. Medifocus (CVE:MFS) Frequently Asked Questions When is Medifocus' next earnings date? Medifocus is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Medifocus. Has Medifocus been receiving favorable news coverage? Headlines about MFS stock have been trending somewhat negative on Friday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Medifocus earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Medifocus. Who are some of Medifocus' key competitors? Some companies that are related to Medifocus include Revive Therapeutics (RVV), Motif Bio (MTFB), BPH Energy (BPH), SalvaRx Group (SALV), Cotinga Pharmaceuticals (COT), Pacgen Life Science (PBS), ImmunoCellular Therapeutics (IMUC), Port Erin Biopharma Investments (PEBI), AngioSoma (SOAN), Asterias Biotherapeutics (AST), Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ) and Almirall (LBTSF). View all competitors. What other stocks do shareholders of Medifocus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifocus investors own include Relypsa (RLYP), Sangamo Therapeutics (SGMO), Regeneron Pharmaceuticals (REGN), Onconova Therapeutics (ONTX), Intec Pharma (NTEC), FireEye (FEYE), Chevron (CVX), BP Prudhoe Bay Royalty Trust (BPT) and Axon Enterprise (AAXN). Who are Medifocus' key executives? Medifocus' management team includes the following people: Dr. William W. Jow, CEO, Pres & Director (Age 61)Mr. Mirsad Jakubovic C.A., M.B.A., Chief Financial Officer (Age 57)Mr. John Mon, VP of Regulatory Affairs & Product Devel. (Age 66)Mr. Douglas Liu, VP of Fin. (Age 55)Dr. Stuart E. Katz M.D., VP of Operations What is Medifocus' stock symbol? Medifocus trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MFS." How do I buy shares of Medifocus? Shares of MFS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Medifocus' stock price today? One share of MFS stock can currently be purchased for approximately C$0.01. How big of a company is Medifocus? Medifocus has a market capitalization of C$1.85 million and generates C$2.23 million in revenue each year. Medifocus employs 7 workers across the globe. What is Medifocus' official website? The official website for Medifocus is www.medifocusinc.com. How can I contact Medifocus? Medifocus' mailing address is The Exchange Tower Suite 1800, 130 King Street West, PO Box 427, TORONTO, ON M5X 1E3, Canada. The company can be reached via phone at +1-905-3197070. This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
